Clinical Trials on Urinary Retention and Symptoms of Overactive Bladder (Urge, Frequency) in Russian Federation

Total 76 results

Joint-Stock Company North-West Center for Evidence-Based...

Unknown

"The Effectiveness of Transvertebral Magnetic Neuromodulation in Patients With Detrusor Overactivity"

Overactive Bladder

Russian Federation
Astellas Pharma Global Development, Inc.

Terminated

A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB) (Dolphin)

Pharmacokinetics of Mirabegron | Overactive Bladder (OAB)

Korea, Republic of, Russian Federation, Turkey
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR) (SOLAR)

Overactive Bladder | Urinary Incontinence | Urge Incontinence

France, Belgium, Spain, Turkey, Australia, Russian Federation, Hungary, Italy, Netherlands, Poland, Czech Republic
R-Pharm
Synergy Research Inc.

Completed

Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder.

Overactive Bladder

Russian Federation
Allergan

Completed

Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

Overactive Bladder

Poland, United Kingdom, Belgium, Russian Federation, Czech Republic, Germany, United States
Meshalkin Research Institute of Pathology of Circulation

Not yet recruiting

The Role of Artificial Intelligence in the Treatment of Abdominal Aortic Aneurysms

Frequency of Embolic Complications | Frequency of Ischemic Complications

Russian Federation
Allergan

Completed

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Overactive Bladder

United Kingdom, Belgium, New Zealand, France, Russian Federation, Czech Republic, United States, Germany, Austria, Poland, Slovakia, Ukraine, Canada, Australia
Allergan

Completed

Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

Overactive Bladder | Urinary Incontinence

Poland, United Kingdom, Belgium, Canada, Russian Federation, United States, Germany, Czechia
I.M. Sechenov First Moscow State Medical University

Unknown

Relationship Between Methods of Bladder Tumor Extraction and Local Recurrence Rate

Bladder Cancer

Russian Federation
Ono Pharmaceutical Co. Ltd

Completed

Study of ONO-8539 in Patients With Overactive Bladder

Overactive Bladder

Poland, Ukraine, Romania, Russian Federation, Czech Republic, Hungary, Netherlands, Sweden, Germany
Allergan

Completed

A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis

Overactive Bladder

Poland, United Kingdom, Portugal, South Africa, Ukraine, Australia, Netherlands, Canada, Singapore, Russian Federation, Germany, Brazil, Austria, Slovakia, Czechia, United States, Taiwan, Italy, France, Belgium, Spain, New Zealand
Astellas Pharma Inc

Completed

Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder. (SHRINK)

Overactive Bladder | Detrusor Overactivity

Belgium, Norway, Spain, Sweden, Italy, Czech Republic, Hungary, France, Canada, Germany, Austria, United Kingdom, Bulgaria, Russian Federation, United States, Poland, Slovakia, Turkey, Israel, Romania
Central Clinical Hospital w/Outpatient Health Center...
I.M. Sechenov First Moscow State Medical University

Unknown

Effectiveness and Safety of Adipose-derived Regenerative Cells for Reduction of Risk of Bladder Neck Contracture

Benign Prostatic Hyperplasia | Bladder Outlet Obstruction | Urinary Bladder Neck Obstruction | Bladder Neck Obstruction

Russian Federation
N.N. Petrov National Medical Research Center of...
The Foundation for Cancer Research Support (RakFond)

Recruiting

Multicentral Preventive Antibiotics With Cystectomy Within Enhanced Recovery After Surgery (MACS)

Bladder Cancer

Russian Federation
Astellas Pharma Europe Ltd.

Completed

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) (BESIDE)

Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Overactive

United States, Armenia, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slov... and more
Bayer

Completed

A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function

Overactive Bladder | Detrusor Overactivity

Spain, Belgium, Canada, Netherlands, Switzerland, Russian Federation, Germany, Israel, Hungary, Portugal, France, Poland, Czech Republic
Astellas Pharma Europe B.V.

Completed

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder (SYNERGY II)

Overactive Bladder | Urgency Incontinence | Urinary Bladder Overactive | Urinary Bladder Diseases\Urologic Diseases

Belgium, Russian Federation, Korea, Republic of, United States, Germany, Spain, Australia, Bulgaria, Canada, Czechia, Denmark, Estonia, Finland, Hungary, Italy, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, ... and more
Astellas Pharma Europe B.V.

Completed

This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder (SYNERGY)

Overactive Bladder | Urgency Incontinence | Urinary Bladder Overactive | Urinary Bladder Diseases\Urologic Diseases

United States, Argentina, Australia, Belgium, Bulgaria, Canada, China, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Netherlands and more
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)

Overactive Bladder

Poland, United Kingdom, Germany, Spain, Netherlands, Belgium, Czech Republic, Italy, Norway, Hungary, Sweden, Denmark, Greece, France, Russian Federation
Pfizer

Completed

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)

Overactive Bladder

Denmark, United States, Canada, Costa Rica, Belgium, Czech Republic, Colombia, Germany, Hungary, Korea, Republic of, Spain, Chile, Taiwan, India, Brazil, Singapore, Greece, Hong Kong, Italy, Sweden, Poland, South Africa, Malaysia, Rom... and more
National Research Center for Preventive Medicine
The League of Clinical Research, Russia

Completed

Primary Prevention Program (3P)

Primary Prevention of Cardiovascular Disease

Russian Federation
Moscow State University of Medicine and Dentistry

Unknown

Efficacy of Botulinum Toxin Type A in Patients With Bladder Pain Syndrome/Intersticial Cystitis and Hunners' Lesions

Interstitial Cystitis

Russian Federation
Moscow State University of Medicine and Dentistry

Recruiting

Intermittent Catheterization Versus Trial Without Catheter

Benign Prostatic Hyperplasia

Russian Federation
Pfizer

Completed

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.

Overactive Bladder

Canada, United States, Costa Rica, Hungary, Slovakia, Spain, Colombia, India, Russian Federation, Ireland, Korea, Republic of, Germany, Sweden, Poland, Bulgaria, Estonia, Brazil, Greece, Latvia, Lithuania, Malaysia, Romania, Singapore, South Africa and more
Joint-Stock Company North-West Center for Evidence-Based...

Not yet recruiting

The Effectiveness of Peripheral Magnetic Stimulation in Men With Lower Urinary Tract Symptoms

Bladder Hypersensitivity

Russian Federation
Pfizer

Completed

A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine

Overactive Bladder

Korea, Republic of, United States, Denmark, Germany, Canada, Hungary, Poland, France, United Kingdom, Slovakia, Sweden, Mexico, Czech Republic, Finland, Italy, Lithuania, Argentina, Chile, Colombia, Egypt, Greece, Norway, Philippines, Russian Federation and more
Astellas Pharma Inc

Completed

Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms (SUNRISE)

Urinary Bladder, Overactive

France, United Kingdom, Belgium, Germany, Spain, Portugal, Greece, Russian Federation, Czech Republic, Poland, Hungary, Italy, Slovakia, Egypt
Astellas Pharma Inc

Completed

Solifenacin Succinate Versus Tolterodine 4mg Once Daily (STAR)

Urinary Bladder, Overactive

France, United Kingdom, Spain, Belarus, Belgium, Ukraine, Denmark, Greece, Russian Federation, Czech Republic, Netherlands, Germany, Hungary, Italy, Slovakia, Sweden, Norway
1st Federal Budgetary Healthcare Institution Volga...

Completed

Efficacy and Safety of the Neodymium Laser in Treatment of Urogenital Tract Diseases in Women

Vulvar Lichen Sclerosus | Pelvic Floor Dysfunction | Genitourinary Syndrome of Menopause

Russian Federation
Urovant Sciences GmbH

Active, not recruiting

Composur: Study to Understand the Performance of Vibegron in Participants With Overactive Bladder (OAB)

Overactive Bladder

United States
Pfizer

Completed

A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.

Urinary Bladder, Overactive

Canada, United States, Germany, Russian Federation, Czechia, Egypt, Bulgaria, Finland, Hungary, Korea, Republic of, Mexico, Poland, South Africa, Sweden, Ukraine
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder (Symphony)

Urologic Diseases | Urinary Bladder, Overactive | Urinary Bladder Diseases | Urological Manifestations | Signs and Symptoms

Belarus, Belgium, Czechia, Denmark, Finland, France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Sweden, Ukraine, United Kingdom
Ipsen

Terminated

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2 (CONTENT2)

Overactive Bladder | Urinary Incontinence

Spain, Israel, Russian Federation, France, Germany, Australia, Belgium, Brazil, United Kingdom, Mexico, Colombia, Chile, Argentina, Lithuania, Peru, Ukraine
Astellas Pharma Europe Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment. (BEYOND)

Urologic Diseases | Urinary Bladder, Overactive | Urinary Bladder Diseases

Greece, Ireland, Armenia, Austria, Belarus, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Hungary, Italy, Kazakhstan, Latvia, Lebanon, Lithuania, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovaki... and more
Allergan

Completed

Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)

Multiple Sclerosis | Urinary Incontinence | Neurogenic Bladder

France, Poland, Portugal, Belgium, Canada, Russian Federation, Czechia, United States
Sanofi

Completed

Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology (Alfahydro)

Hydronephrosis | Neurogenic Bladder

Canada, Poland, Russian Federation, Turkey, Bulgaria, India, Malaysia, Serbia, Slovakia, Taiwan, Estonia, Singapore
Astellas Pharma Inc

Completed

Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (SCORPIO)

Urinary Bladder, Overactive

Australia, Belgium, France, Spain, Sweden, Bulgaria, Romania, Italy, Greece, South Africa, Austria, Poland, United Kingdom, Hungary, Denmark, Netherlands, Switzerland, Ireland, Lithuania, Russian Federation, Germany, Latvia, Slovakia, Finlan... and more
D.O. Ott Research Institute of Obstetrics, Gynecology...

Completed

Autologous Bone Marrow-derived Mesenchymal Stem Cells for Atrophic Endometrium in Patients With Repeated IVF Failures

Infertility, Female | Asherman Syndrome | Infertility of Uterine Origin

Russian Federation
Astellas Pharma Inc

Completed

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (TAURUS)

Urinary Bladder, Overactive

Canada, Poland, Belgium, Spain, Sweden, United States, Romania, Italy, France, Austria, United Kingdom, Germany, Hungary, Australia, Denmark, Netherlands, Switzerland, Lithuania, Russian Federation, Latvia, South Africa, Slovakia, F... and more
I.M. Sechenov First Moscow State Medical University

Recruiting

Intermittent Hypoxic-hyperoxic Training in Patients With Cardiovascular Pathology After COVID-19 Infection.

COVID-19 | Quality of Life | Hypertension | Arrhythmia | Chronic Heart Failure | Endothelial Dysfunction | Conduct Disorder | Oxygen Consumption | Diastolic Dysfunction | Chronic Coronary Syndrome | Exercise Tolerance

Russian Federation
Sanofi

Completed

Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction (ALFACHIN)

Neurogenic Urinary Bladder

United States, France, Canada, Poland, Germany, Portugal, Spain, Turkey, Bulgaria, Estonia, India, Malaysia, Philippines, Russian Federation, Serbia, Singapore, Slovakia, Taiwan
Tyumen State Medical Academy

Unknown

Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants

Hyperandrogenism | Polycystic Ovarian Syndrome | Menstrual Irregularities

Russian Federation
Materia Medica Holding

Recruiting

Clinical Trial of the Efficacy and Safety of Raphamin in Prevention of Recurrences of Chronic Bacterial Cystitis

Cystitis Chronic | Cystitis Bacterial | Recurrence of Chronic Bacterial Cystitis

Russian Federation
Tomsk National Research Medical Center of the Russian...

Completed

Phenotypic Spectrum of CTCs in Tumors of the Female Reproductive System (CTCs)

Breast Cancer | Ovarian Cancer | Endometrial Cancer

Russian Federation
Astellas Pharma Inc

Completed

Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis (SONIC)

Multiple Sclerosis | Spinal Cord Diseases | Neurogenic Bladder

Australia, France, Belgium, Germany, Netherlands, Italy, Spain, United Kingdom, Hungary, Czechia, Russian Federation
Boehringer Ingelheim

Completed

Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder

Bladder, Neurogenic

Belgium, Spain, United States, India, South Africa, Philippines, Italy, Korea, Republic of, Russian Federation, Germany, Brazil, Mexico, Ukraine
Astellas Pharma Europe B.V.

Completed

A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis (SERENITY)

Interstitial Cystitis | Bladder Pain Syndrome

Spain, Russian Federation, Belgium, Czechia, Germany, Hungary, Latvia, Netherlands, Poland, United Kingdom
Boehringer Ingelheim

Completed

PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder

Bladder, Neurogenic

Belgium, Spain, United States, South Africa, Philippines, Italy, Korea, Republic of, Russian Federation, Germany, India, Brazil, Canada, Mexico, Ukraine
Astellas Pharma Europe B.V.

Completed

A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC) (AMARANTH)

Pain | Urologic Diseases | Cystitis, Interstitial | Urinary Bladder Disease

Belgium, Czechia, Denmark, Germany, Latvia, Lithuania, Netherlands, Poland, Portugal, Romania, Russian Federation, Spain
Swedish Orphan Biovitrum

Terminated

Comparison of rhBSSL With Placebo When Added to Infant Formula or Pasteurized Breast Milk During 4 Weeks of Treatment in Preterm Infants (LAIF)

Prevention of Growth Restriction

Belgium, France, Germany, Hungary, Italy, Poland, Spain, Sweden, Czech Republic, Russian Federation

Clinical Trials on Urinary Retention and Symptoms of Overactive Bladder (Urge, Frequency) in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations